SeaStar Medical Posts Wider Loss In Q3 On Higher R&D Expenses

SeaStar Medical (ICU) reported a wider Q3 net loss of $4.53M due to higher R&D expenses, though revenue surged 247% to $0.635M. The company's QUELIMMUNE device showed positive clinical results, and its SCD program is progressing. ICU stock closed at $1.92, down 15.62% in overnight trading.

Original reporting
Published Nov 12, 2026, 8:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ICU
Bearish
medium confidence
Mentioned
$ICU
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$ICUBearishMed
01

Why it matters

The Q3 earnings release provides the first detailed financial snapshot of the company's expanded R&D spend and cash position.

02

Market read

First‑time Q3 earnings disclosure for a micro‑cap biotech, indicating short‑term downside risk but long‑term growth potential.

03

What to watch

Potential upside from upcoming CMS billing codes and pending adult trial data may improve future cash flow.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

SeaStar Medical is a commercial‑stage company developing the QUELIMMUNE device for pediatric sepsis‑associated AKI and an adult SCD platform.

Company-level read

Ticker impact

$ICUBearishMedium confidence
Context

SeaStar Medical Holding Corp (ICU) posted Q3 results with a wider net loss and higher R&D spend, a primary earnings disclosure.

Expected impact

likely downside as investors price the expanded loss and higher cash burn

Evidence & confidence

Earnings miss and higher expenses typically trigger sell pressure, especially for a micro‑cap with limited liquidity.

Market effects

Highlights continued investment in pediatric sepsis therapies, may spur interest in niche biotech sector.

Limited to U.S. micro‑cap biotech space; no broader regional effect.

Minimal global impact; primarily relevant to investors tracking early‑stage medical device firms.

Counterpoint

The surge in net revenue and FDA Breakthrough designation could offset loss concerns for longer‑term investors.

Key entities

  • SeaStar Medical Holding Corp

    Developer of QUELIMMUNE and SCD devices, ticker ICU.

  • FDA

    Granted Breakthrough Device designation for SCD.

Related articles

$ICUHigh

SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates

SeaStar Medical Holding Corp (ICU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates Continued adoption of the QUELIMMUNE ® therapy yielded 247% increase in net revenue compared to the third quarter of 2025 Achieved nearly 75% enrollment in the NEUTRALIZE-AKI p